Efficacy of ultrasound renal denervation reducing blood pressure: a systematic review and meta-analysis.

IF 1.1 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS

REC Interventional Cardiology Pub Date : 2025-04-29 eCollection Date: 2025-01-01 DOI:10.24875/RECICE.M25000509

Juan Miguel Guerrero-Hernández, Cristian Jesús Palomino-Ojeda, Lissette Haydee García-Mena, José Luis Maldonado-García, Óscar Ángel Vedia-Cruz, José Antonio García-Donaire, Iván Javier Núñez-Gil

{"title":"Efficacy of ultrasound renal denervation reducing blood pressure: a systematic review and meta-analysis.","authors":"Juan Miguel Guerrero-Hernández, Cristian Jesús Palomino-Ojeda, Lissette Haydee García-Mena, José Luis Maldonado-García, Óscar Ángel Vedia-Cruz, José Antonio García-Donaire, Iván Javier Núñez-Gil","doi":"10.24875/RECICE.M25000509","DOIUrl":null,"url":null,"abstract":"Introduction and objectives: Ultrasound renal denervation (uRDN) has emerged as an innovative therapeutic approach for the treatment of hypertension. However, its efficacy compared to medication remains uncertain. We aimed to assess the efficacy profile of uRDN vs sham groups focusing on its impact on daytime ambulatory blood pressure, 24-hour blood pressure, home blood pressure and office blood pressure.Methods: We conducted a systematic search across Embase, PubMed, and Cochrane Library databases from their inception up 1 November 2024 to identify randomized controlled trials evaluating the efficacy of uRDN. Statistical analyses were performed using RevMan 6.3 software, utilizing the mean and standard deviation method to calculate mean differences with a 95% confidence interval (95%CI).Results: A total of 4 studies were included in the final analysis with 642 patients. uRDN significantly reduced daytime ambulatory systolic blood pressure (SBP) (-5.12 mmHg; 95%CI, -6.07 to -4.16; P ≤ .00001), 24-h SBP (-4.87 mmHg; 95%CI, -6.53 to -3.21]; P ≤ .00001), office SBP (-5.03 mmHg; 95%CI, -6.27 to -3.79; P ≤ .00001) and showed a decrease in patient medication 6 months after the procedure.Conclusions: Using uRDN leads to a lower blood pressure in patients within 2 months following the procedure. Additionally, after 6 months a significant decrease in drug use is observed.This meta-analysis protocol was registered on PROSPERO on 7 July 2024 (CRD42024562852).","PeriodicalId":34295,"journal":{"name":"REC Interventional Cardiology","volume":"7 3","pages":"154-163"},"PeriodicalIF":1.1000,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12418244/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"REC Interventional Cardiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.24875/RECICE.M25000509","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction and objectives: Ultrasound renal denervation (uRDN) has emerged as an innovative therapeutic approach for the treatment of hypertension. However, its efficacy compared to medication remains uncertain. We aimed to assess the efficacy profile of uRDN vs sham groups focusing on its impact on daytime ambulatory blood pressure, 24-hour blood pressure, home blood pressure and office blood pressure.

Methods: We conducted a systematic search across Embase, PubMed, and Cochrane Library databases from their inception up 1 November 2024 to identify randomized controlled trials evaluating the efficacy of uRDN. Statistical analyses were performed using RevMan 6.3 software, utilizing the mean and standard deviation method to calculate mean differences with a 95% confidence interval (95%CI).

Results: A total of 4 studies were included in the final analysis with 642 patients. uRDN significantly reduced daytime ambulatory systolic blood pressure (SBP) (-5.12 mmHg; 95%CI, -6.07 to -4.16; P ≤ .00001), 24-h SBP (-4.87 mmHg; 95%CI, -6.53 to -3.21]; P ≤ .00001), office SBP (-5.03 mmHg; 95%CI, -6.27 to -3.79; P ≤ .00001) and showed a decrease in patient medication 6 months after the procedure.

Conclusions: Using uRDN leads to a lower blood pressure in patients within 2 months following the procedure. Additionally, after 6 months a significant decrease in drug use is observed.This meta-analysis protocol was registered on PROSPERO on 7 July 2024 (CRD42024562852).

Abstract Image

查看原文本刊更多论文

超声肾去神经术降低血压的疗效：系统回顾和荟萃分析。

介绍和目的：超声肾去神经（uRDN）已成为一种创新的治疗高血压的方法。然而，与药物相比，其疗效仍不确定。我们的目的是评估uRDN组与假手术组的疗效概况，重点关注其对日间动态血压、24小时血压、家庭血压和办公室血压的影响。方法：我们对Embase、PubMed和Cochrane图书馆数据库进行了系统检索，从其建立到2024年11月1日，以确定评估uRDN疗效的随机对照试验。采用RevMan 6.3软件进行统计分析，采用均数和标准差法计算均数差异，95%置信区间（95% ci）。结果：最终纳入4项研究，642例患者。uRDN显著降低日间动态收缩压（SBP）（-5.12 mmHg; 95%CI, -6.07至-4.16;P≤0.00001），24小时收缩压（-4.87 mmHg; 95%CI, -6.53至-3.21];P≤0.00001），办公室收缩压（-5.03 mmHg; 95%CI, -6.27至-3.79;P≤0.00001），并在术后6个月患者用药减少。结论：使用uRDN可在手术后2个月内降低患者的血压。此外，6个月后，药物使用显著减少。该荟萃分析方案于2024年7月7日在PROSPERO注册（CRD42024562852）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊